Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
SLNO Stock Chart & Stats
$31.84
-$1.55(-3.35%)
At close: 4:00 PM EST
$31.84
-$1.55(-3.35%)
Day’s Range― - ―
52-Week Range$30.11 - $90.32
Previous CloseN/A
Volume118.06K
Average Volume (3M)1.44M
Market Cap
$1.64B
Enterprise Value$1.64B
Total Cash (Recent Filing)$305.47M
Total Debt (Recent Filing)$2.69M
Price to Earnings (P/E)117.9
Beta0.52
Next Earnings
May 12, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding51,624,386
10 Day Avg. Volume1,586,270
30 Day Avg. Volume1,439,468
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)5.47
Price to Sales (P/S)12.93
P/FCF Ratio52.69
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue8.63
Enterprise Value/Gross Profit8.75
Enterprise Value/Ebitda57.88
Forecast
1Y Price Target
$101.09Price Target Upside217.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)4.04
Revenue Forecast (FY)$472.71M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionAnalyst notes growing adoption among specialist prescribers, with many repeat prescribers driving broader national prescribing patterns and supporting continued new patient uptake.
Financial PositionCompany has achieved profitability and positive operating cash flow, providing financial flexibility to pursue acquisitions, licensing, or capital returns that could enhance shareholder value.
Payer ReimbursementAnalyst reports widening payer reimbursement across commercial plans, Medicaid, and Medicare, which reduces access barriers and supports higher patient initiation rates.
Bears Say
New Patient Start MomentumAnalyst highlights a slowdown in new patient starts and wide variability in uptake scenarios, creating uncertainty around future sales momentum and investor expectations.
Patient Eligibility ConstraintsCertain patient groups, including those with specific heart conditions or gout and patients taking particular medications, are likely ineligible for therapy, limiting the addressable market.
Treatment DiscontinuationAnalyst flags that rising treatment discontinuations due to adverse events could temper overall uptake and weaken long-term patient retention.
Soleno Therapeutics News
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $30.11 and its highest was $90.32 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Soleno Therapeutics Inc’s market cap is $1.64B.
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is May 12, 2026 which is in 46 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on Feb 25, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.711 by $0.089.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is 0.66.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 51,624,386 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of $0.8 in its last earnings report, beating expectations of $0.711. Following the earnings report the stock price went down -7.12%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Currently, no hedge funds are holding shares in SLNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Soleno Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$101.09 (217.49% Upside)
$101.09 (217.49% Upside)
Blogger Sentiment
Bearish
SLNO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 773.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 13.1%
Last 30 Days ▲ 13.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.49%
12-Months-Change
Fundamentals
Return on Equity
5.90%
Trailing 12-Months
Asset Growth
70.36%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SLNO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong commercial launch and material financial progress — meaningful sequential revenue growth (~40% Q/Q), positive operating cash flow and full-year profitability — alongside encouraging commercial metrics (1,250 start forms, 859 active patients, 630 prescribers and coverage of >180M lives). Key near-term risks flagged include EU regulatory uncertainty, anticipated increases in COGS as inventory normalizes, seasonality-driven Q1 gross-to-net effects, elevated SG&A for continued launch investment, and an expected long-term discontinuation range of 15%–20%. On balance, the positive financial and commercial momentum and ample cash runway outweigh the outlined challenges.View all SLNO earnings summariesSLNO Stock 12 Month Forecast
Average Price Target
$101.09
▲(217.49% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---